Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73) YoY; Collaboration Revenue Of 6M
Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73) YoY; Collaboration Revenue Of 6M
Financial Results
財務業績
As of December 31, 2023, Coya had cash and cash equivalents of $32.6 million and received an additional $7.5 million in January from Dr. Reddy's as an upfront payment as part of the COYA 302 licensing arrangement.
截至2023年12月31日，作爲COYA 302許可安排的一部分，Coya擁有3,260萬美元的現金及現金等價物，並於1月份從雷迪博士那裏額外獲得了750萬澳元的預付款。
Research and development (R&D) expenses were $5.5 million for the year ended December 31, 2023, compared to $4.4 million for the year ended December 31, 2022. The change was primarily due to a $2.2 million increase in our preclinical expenses and a $0.5 million increase in internal research and development expenses, partially offset by a $1.4 million decrease in costs attributable to our sponsored research agreement with Houston Methodist Hospital and a $0.3 million decrease in costs for our clinical product candidate.
截至2023年12月31日的財年，研發（R&D）支出爲550萬美元，而截至2022年12月31日的年度爲440萬美元。這一變化主要是由於我們的臨床前支出增加了220萬美元，內部研發費用增加了50萬美元，但部分被140萬美元的成本減少所抵消，這歸因於我們與休斯敦衛理公會醫院的贊助研究協議，以及我們的臨床候選產品成本減少了30萬美元。
General and administrative expenses were $7.8 million for the year ended December 31, 2023, and $4.8 million for the year ended December 31, 2022, a change of approximately $3.0 million. The increase was primarily due to an increase in personnel related expenses arising from increases in employee headcount and an increase in our professional fees and consulting fees as we expanded our operations to support our research and development efforts.
截至2023年12月31日止年度的一般和管理費用爲780萬美元，截至2022年12月31日止年度的一般和管理費用爲480萬美元，變動約300萬美元。增長的主要原因是員工人數增加導致的人事相關費用增加，以及隨着我們擴大業務以支持研發工作，我們的專業費用和諮詢費也有所增加。
Net loss was $8.0 million for the year ended December 31, 2023, compared to net loss of $12.2 million for the year ended December 31, 2022.
截至2023年12月31日止年度的淨虧損爲800萬美元，而截至2022年12月31日止年度的淨虧損爲1,220萬美元。
譯文內容由第三人軟體翻譯。